Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress Meeting Abstract
| Authors: | Cheng, A.; Abou-Alfa, G.; Ren, Z.; Assenat, E.; Cubillo, A.; Pluntke, S.; Rimassa, L.; Ross, P.; Wyrwicz, L.; Hou, J.; Li, C.; Wu, J.; Ducreux, M. |
| Abstract Title: | Efficacy, safety, and pharmacokinetics of the anti-programmed cell death receptor-1 (PD-1) monoclonal antibody, tislelizumab (BGB-A317) in a phase 2, open-label, multicenter study to investigate in patients with unresectable hepatocellular carcinoma - Trial in progress |
| Meeting Title: | ESMO 20th World Congress on Gastrointestinal Cancer |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2018 Jun 20-23 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-06-01 |
| Start Page: | mdy151.099 |
| Language: | English |
| ACCESSION: | WOS:000439970900144 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy151.099 |
| Notes: | Meeting Abstract: P-100 -- Appears on pages v27-v28 of the abstract book -- Source: Wos |
